secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001493152-25-018687
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem shareholders reject merger with Aditxt; merger terminated
----------------------------------------------------------------

- Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.
- Evofem terminates Merger Agreement with Aditxt effective Oct 20, 2025; no termination fee paid.
- Company pivots to seek national stock listing and growth capital, targeting sustainable positive EBITDA in 2027.
- CEO states collaboration with Aditxt for Mitomic diagnostic tests continues under September 2024 agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225018687/0001493152-25-018687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225018687/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer